Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Ultomiris Approval Rounds Off A Good Week For Alexion’s Complement Franchise

Executive Summary

A first EU approval for Ultomiris added to a label expansion for Soliris in the US made for a good seven days for Alexion’s C5 product portfolio.

You may also be interested in...



Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

ViiV’s Potential HIV Blockbuster Among Latest Drugs To Win EMA Nod

A total of 13 new drugs have been recommended for pan-EU approval, while one has failed to meet the European Medicines Agency’s standards.

Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris

Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop new ultra-rare disease therapies with significant commercial potential.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel